Avoro Capital Advisors LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Avoro Capital Advisors LLC disclosed 30 US equity positions worth $7.7bn in its Q3 2025 13F filing. The largest position was ASND at 13.1% of the reported book, followed by UTHR and MDGL. Against the Q2 2025 filing, it opened 3 new positions, added to 11 and reduced 11 among the top 30 holdings.
What did Avoro Capital Advisors LLC own in Q3 2025? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA | Healthcare | 13.1% | $1.0bn | 5,110,000 | 3% | added |
| 2 | UTHR UNITED THERAPEUTICS CORP | Healthcare | 11.0% | $847.7m | 2,022,222 | -15% | reduced |
| 3 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 10.9% | $840.7m | 1,833,000 | -2% | reduced |
| 4 | ARGX ARGENX SE | Healthcare | 9.4% | $730.2m | 990,000 | -16% | reduced |
| 5 | KRYS KRYSTAL BIOTECH INC | Healthcare | 6.3% | $490.4m | 2,777,777 | 4% | added |
| 6 | ARWR ARROWHEAD PHARMACEUTICALS INC. | Healthcare | 4.9% | $375.9m | 10,900,000 | 3% | added |
| 7 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 4.6% | $359.4m | 6,350,000 | -3% | reduced |
| 8 | MERUS N V | 4.3% | $333.5m | 3,542,500 | 12% | added | |
| 9 | RNAGBP AVIDITY BIOSCIENCES INC | 4.3% | $333.1m | 7,645,000 | 8% | added | |
| 10 | APLSUSD APELLIS PHARMACEUTICALS INC. | 3.6% | $276.6m | 12,222,222 | 0% | held | |
| 11 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.4% | $262.1m | 10,808,080 | 116% | added | |
| 12 | QURE UNIQURE NV | 3.4% | $259.4m | 4,444,444 | 23% | added | |
| 13 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.8% | $216.8m | 5,400,000 | 0% | held |
| 14 | AKERO THERAPEUTICS INC | 2.4% | $187.8m | 3,955,555 | 13% | added | |
| 15 | VERA VERA THERAPEUTICS INC | Healthcare | 2.3% | $180.5m | 6,210,000 | -1% | reduced |
| 16 | SLNOEUR SOLENO THERAPEUTICS INC | 2.3% | $174.3m | 2,577,777 | 26% | added | |
| 17 | GPCR STRUCTURE THERAPEUTICS INC. | Healthcare | 1.9% | $144.4m | 5,155,555 | – | new |
| 18 | TRML TOURMALINE BIO INC | 1.6% | $122.2m | 2,555,555 | 0% | held | |
| 19 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.6% | $119.8m | 10,250,000 | 39% | added |
| 20 | AM6 AMICUS THERAPEUTICS INC. | 1.5% | $118.4m | 15,025,000 | -17% | reduced | |
| 21 | ETNBGBP 89BIO INC | 1.2% | $93.9m | 6,387,790 | -5% | reduced | |
| 22 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.9% | $71.0m | 21,700,000 | 0% | held |
| 23 | ALKS ALKERMES PLC | Healthcare | 0.9% | $67.2m | 2,240,000 | -23% | reduced |
| 24 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.3% | $25.6m | 1,333,340 | – | new |
| 25 | SEPN SEPTERNA INC | 0.3% | $25.2m | 1,337,500 | 8% | added | |
| 26 | MNKD MANNKIND CORP | Healthcare | 0.3% | $24.0m | 4,468,877 | -24% | reduced |
| 27 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.2% | $14.3m | 2,000,000 | -52% | reduced |
| 28 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 0.1% | $9.5m | 1,250,000 | -72% | reduced |
| 29 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 0.1% | $5.4m | 2,849,402 | 0% | held |
| 30 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.1% | $4.6m | 545,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.